Palonosetron
- Generic Name
- Palonosetron
- Brand Names
- Akynzeo, Aloxi, Palonosetron Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24N2O
- CAS Number
- 135729-56-5
- Unique Ingredient Identifier
- 5D06587D6R
- Background
Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.
- Indication
For the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy. Also used for the prevention of postoperative nausea and vomiting for up to 24 hours post operation.
- Associated Conditions
- Nausea caused by Chemotherapy, Post Operative Nausea and Vomiting (PONV), Acute chemotherapy-induced nausea and vomiting, Delayed chemotherapy-induced nausea and vomiting
AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors
- Conditions
- LeukemiaLymphoma
- Interventions
- First Posted Date
- 2006-12-22
- Last Posted Date
- 2009-09-18
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 196
- Registration Number
- NCT00415103
- Locations
- 🇪🇸
Hospital Universitario La Paz, Madrid, Spain
🇪🇸Hospital Universitario Marqués de Valdecilla, Santander, Spain
🇪🇸Hospital Universitario la Princesa, Madrid, Spain
Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2012-05-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00412425
- Locations
- 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States
Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)
- Conditions
- NauseaSarcomaVomiting
- Interventions
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT00410488
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
- Conditions
- Colorectal CancerNausea and Vomiting
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 54
- Registration Number
- NCT00381862
- Locations
- 🇺🇸
St. Josephs/Cander Hospital, Savannah, Georgia, United States
🇺🇸Kaiser Permanente, Hilo, Hawaii, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic Chemotherapy
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2011-07-07
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1140
- Registration Number
- NCT00359567
- Locations
- 🇯🇵
National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan
Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
- Conditions
- Male Breast CancerNausea and VomitingStage IIIA Breast CancerStage I Breast CancerStage II Breast Cancer
- Interventions
- Procedure: quality-of-life assessmentProcedure: nausea and vomiting therapyProcedure: management of therapy complicationsOther: survey administration
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 41
- Registration Number
- NCT00343863
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
- Conditions
- Unspecified Adult Solid Tumor, Protocol SpecificNausea and Vomiting
- Interventions
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 1428
- Registration Number
- NCT00343460
- Locations
- 🇺🇸
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Palo Verde Hematology Oncology - Glendale, Glendale, Arizona, United States
🇺🇸Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States
Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT00306735
- Locations
- 🇺🇸
Indiana Blood and Marrow Transplantation, Beech Grove, Indiana, United States
🇺🇸Cornell Medical Center, New York, New York, United States
🇺🇸Wake Forest Medical Center, Winston-Salem, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.